Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG942

—

ae85eb7d-ad48-5817-a3dc-d4118655e563

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • UV_RESPONSE_DN+0.347
  • BILE_ACID_METABOLISM+0.297
  • PROTEIN_SECRETION+0.276
  • KRAS_SIGNALING_DN+0.259
  • PANCREAS_BETA_CELLS+0.253
  • SPERMATOGENESIS+0.204
  • HEDGEHOG_SIGNALING+0.185
  • COAGULATION+0.181
  • ANDROGEN_RESPONSE+0.172
  • ESTROGEN_RESPONSE_EARLY+0.172

Top 10 suppressed

  • MYC_TARGETS_V2-0.588
  • OXIDATIVE_PHOSPHORYLATION-0.459
  • TNFA_SIGNALING_VIA_NFKB-0.430
  • ALLOGRAFT_REJECTION-0.412
  • IL6_JAK_STAT3_SIGNALING-0.406
  • MYC_TARGETS_V1-0.401
  • DNA_REPAIR-0.386
  • INTERFERON_GAMMA_RESPONSE-0.381
  • E2F_TARGETS-0.374
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.354

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
165f86d9a-828b-4e8b-a656-38baba5a54f7
colon-landscapes@1
——0.900
2MNG355
mng-umap@100
——0.859
3C3N-03921
lung-landscapes@6
—cohortA10.858
4SRR660945
brain-umap@2
GTEX—0.850
5TCGA-50-5942-01A-21R-1755-07
lung-landscapes@6
—cohortA10.846
6MNG792
mng-umap@100
——0.838
7SRR1359123
brain-umap@2
GTEX—0.838
8TCGA-50-5944-01A-11R-1755-07
lung-landscapes@6
—cohortA10.831
9SRR8613701
breast-umap@18
—A0.827
10BS_A14Z8BBK
medullo-epn-umap@date-based
MedMedulloblastoma0.826

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
UV_RESPONSE_DN0.347Inavolisib— uncovered
BILE_ACID_METABOLISM0.297Inavolisib— uncovered
PROTEIN_SECRETION0.276Remibrutinib— uncovered
KRAS_SIGNALING_DN0.259Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.253Cobimetinib— uncovered
SPERMATOGENESIS0.204Inavolisib— uncovered
HEDGEHOG_SIGNALING0.185Inavolisib— uncovered
COAGULATION0.181Binimetinib— uncovered
ANDROGEN_RESPONSE0.172Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.172Inavolisib— uncovered
MYOGENESIS0.164Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.128Idelalisib— uncovered
TGF_BETA_SIGNALING0.120Inavolisib— uncovered
APICAL_JUNCTION0.115Inavolisib— uncovered
APICAL_SURFACE0.094Temsirolimus— uncovered
HEME_METABOLISM0.075Temsirolimus— uncovered
XENOBIOTIC_METABOLISM0.055Inavolisib— uncovered
KRAS_SIGNALING_UP0.032Inavolisib— uncovered
FATTY_ACID_METABOLISM0.010Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.006Inavolisib— uncovered